<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076919</url>
  </required_header>
  <id_info>
    <org_study_id>C-13-007</org_study_id>
    <nct_id>NCT02076919</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration</brief_title>
  <official_title>A Randomized, Double-Masked, Vehicle-Controlled, First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Topically Delivered LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study is to assess the local ocular and systemic safety
      and tolerability of LHA510 eye drops when administered at various concentrations and dosing
      frequencies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human study was conducted in two parts. Part 1 was a single ascending dose
      (SAD) design to assess the local ocular and systemic safety and tolerability of a single
      topical eye drop of LHA510 administered at various concentrations. Four separate cohorts of
      unique elderly subjects (55 to 80 years) were utilized, with each cohort randomized to
      receive either topical LHA510 or vehicle in a 3:1 ratio as a single dose. A disposition
      evaluation was performed 7 days later. Part 2 was a multiple ascending dose (MAD) design to
      assess the local ocular and systemic safety and tolerability of LHA510 administered at
      various concentrations and dosing frequencies. Six separate cohorts of unique AMD subjects
      were utilized, with each cohort randomized to receive either topical LHA510 or vehicle in a
      3:1 ratio for 7 days. A disposition evaluation was performed 14 days after the first dose of
      study drug. A review of all available safety data was conducted by the Sponsor and the PI(s)
      prior to dose escalation (cohort progression). The same concentrations levels were used in
      Part 1 and Part 2 and are ordered as Lowest, Next Lowest, Next Highest, and Highest.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 1</measure>
    <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
    <description>A serious adverse event (SAE) was defined as any event which is fatal or life-threatening, which requires or prolongs hospitalization, which is significantly or permanently disabling or incapacitating, which constitutes a congenital anomaly or a birth defect, or which is medically significant, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 2</measure>
    <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
    <description>A serious adverse event (SAE) was defined as any event which is fatal or life-threatening, which requires or prolongs hospitalization, which is significantly or permanently disabling or incapacitating, which constitutes a congenital anomaly or a birth defect, or which is medically significant, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Experiencing a Non-serious Adverse Event, Part I</measure>
    <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Experiencing a Non-serious Adverse Event, Part 2</measure>
    <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration [Mass / Volume] (Cmax), Part 2</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method.Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Reach the Maximum Concentration After Drug Administration [Time] (Tmax), Part 2</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [Mass x Time/Volume] (AUClast), Part 2</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Terminal Elimination Half-life [Time] (T1/2), Part 2</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 1</measure>
    <time_frame>Day 1: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
    <description>Diastolic blood pressure (pressure in the arteries when the heart rests between beats) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 1</measure>
    <time_frame>Day 1: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
    <description>Systolic blood pressure (pressure when the heart is contracting) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 1</measure>
    <time_frame>Day 1: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
    <description>Mean arterial blood pressure (average pressure in the arteries during one cardiac cycle) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 2</measure>
    <time_frame>Day 1 and 7: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
    <description>Diastolic blood pressure (pressure in the arteries when the heart rests between beats) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 2</measure>
    <time_frame>Day 1 and 7: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
    <description>Systolic blood pressure (pressure when the heart is contracting) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 2</measure>
    <time_frame>Day 1 and 7: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
    <description>Mean arterial blood pressure (average pressure in the arteries during one cardiac cycle) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>LHA510 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHA510 Vehicle Part 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHA510 Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHA510 Vehicle Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHA510 Ophthalmic Suspension</intervention_name>
    <description>Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2</description>
    <arm_group_label>LHA510 Part 1</arm_group_label>
    <arm_group_label>LHA510 Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHA510 Vehicle</intervention_name>
    <description>Inactive ingredients used for masking purposes</description>
    <arm_group_label>LHA510 Vehicle Part 1</arm_group_label>
    <arm_group_label>LHA510 Vehicle Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent.

          -  Vital signs within the following ranges:

               -  oral body temperature between 35.0-37.5 °C

               -  systolic blood pressure, 90-150 mm Hg

               -  diastolic blood pressure, 50-90 mm Hg

               -  pulse rate, 40 - 100 bpm.

          -  Weigh at least 50 kg.

          -  Able to communicate well with the investigator.

          -  Able to understand and comply with the requirements of the study.

        Additional eligibility criteria for Part 2 (AMD subjects):

          -  Evidence of AMD in one or both eyes.

          -  Age 55-90.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Any currently active ocular condition that requires use of topical eye drops.

          -  Use of contact lens over the course of the study.

          -  Abnormal corneal examination results at screening or eligibility.

          -  History of any ocular surgery within the past 6 months prior to study participation.

          -  Use of other investigational drugs within 30 days of enrollment.

          -  History of hypersensitivity or allergy to any of the study drugs (including
             fluorescein) or to drugs of similar chemical classes.

          -  History of clinically significant ECG abnormalities, or any ECG abnormality at
             screening or eligibility.

          -  Known history or current clinically significant arrhythmias.

          -  History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years.

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential.

          -  Use of any prohibited medication as specified in the protocol.

          -  Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial
             dosing.

          -  Low hemoglobin levels at screening or eligibility as specified in the protocol.

          -  Significant illness as specified in the protocol.

          -  History of drug or alcohol abuse within the 12 months prior to dosing.

        Additional exclusion criteria for Part 1 (healthy subjects):

          -  Abnormal thickness of the central retinal subfield on OCT at screening.

          -  History of any chronic eye disease other than refractive error, incipient cataract,
             strabismic amblyopia, or anisometropic amblyopia.

        Additional exclusion criteria for Part 2 (AMD subjects):

          -  Any of the following treatments to the study eye within 28 days prior to dosing:
             ranibizumab (Lucentis®), aflibercept (Eylea®), bevacizumab (Avastin®), pegaptanib
             (Macugen®), or any other VEGF inhibitor.

          -  Patients who have required and received regular monthly injections of these drugs in
             the months preceding the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Maietta, BSc</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <results_first_submitted>June 30, 2015</results_first_submitted>
  <results_first_submitted_qc>August 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2015</results_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LHA510</keyword>
  <keyword>First in human</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Elderly</keyword>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>Ocular</keyword>
  <keyword>Eye drop</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a single investigational site located in the US.</recruitment_details>
      <pre_assignment_details>Of the 110 enrolled, 30 subjects were exited as screen failures prior to randomization. This reporting group includes all randomized subjects (80).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LHA510, Part 1</title>
          <description>Ophthalmic suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1</description>
        </group>
        <group group_id="P2">
          <title>Vehicle, Part 1</title>
          <description>Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1</description>
        </group>
        <group group_id="P3">
          <title>LHA510, Part 2</title>
          <description>Ophthalmic suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2</description>
        </group>
        <group group_id="P4">
          <title>Vehicle, Part 2</title>
          <description>Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all enrolled subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>LHA510 Lowest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="B2">
          <title>LHA510 Next Lowest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="B3">
          <title>LHA510 Next Highest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="B4">
          <title>LHA510 Highest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="B5">
          <title>Vehicle, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="B6">
          <title>LHA510 Lowest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="B7">
          <title>LHA510 Next Lowest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="B8">
          <title>LHA510 Next Highest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="B9">
          <title>LHA510 Highest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="B10">
          <title>LHA510 Highest BID, Part 2</title>
          <description>1 drop instilled in the study eye twice daily for 7 days</description>
        </group>
        <group group_id="B11">
          <title>LHA510 Highest TID, Part 2</title>
          <description>1 drop instilled in the study eye three times daily for 7 days</description>
        </group>
        <group group_id="B12">
          <title>Vehicle, Part 2</title>
          <description>1 drop instilled in the study eye once, twice, or three times daily for 7 days</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="12"/>
            <count group_id="B13" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>55-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 1</title>
        <description>A serious adverse event (SAE) was defined as any event which is fatal or life-threatening, which requires or prolongs hospitalization, which is significantly or permanently disabling or incapacitating, which constitutes a congenital anomaly or a birth defect, or which is medically significant, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 1</title>
          <description>A serious adverse event (SAE) was defined as any event which is fatal or life-threatening, which requires or prolongs hospitalization, which is significantly or permanently disabling or incapacitating, which constitutes a congenital anomaly or a birth defect, or which is medically significant, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>This analysis population includes all enrolled subjects in Part 1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 2</title>
        <description>A serious adverse event (SAE) was defined as any event which is fatal or life-threatening, which requires or prolongs hospitalization, which is significantly or permanently disabling or incapacitating, which constitutes a congenital anomaly or a birth defect, or which is medically significant, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
          <group group_id="O7">
            <title>Vehicle, Part 2</title>
            <description>1 drop instilled in the study eye once, twice, or three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 2</title>
          <description>A serious adverse event (SAE) was defined as any event which is fatal or life-threatening, which requires or prolongs hospitalization, which is significantly or permanently disabling or incapacitating, which constitutes a congenital anomaly or a birth defect, or which is medically significant, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration [Mass / Volume] (Cmax), Part 2</title>
        <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method.Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
        <time_frame>Up to Day 15</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration [Mass / Volume] (Cmax), Part 2</title>
          <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method.Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O5" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O6" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Reach the Maximum Concentration After Drug Administration [Time] (Tmax), Part 2</title>
        <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
        <time_frame>Up to Day 15</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Reach the Maximum Concentration After Drug Administration [Time] (Tmax), Part 2</title>
          <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O5" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O6" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [Mass x Time/Volume] (AUClast), Part 2</title>
        <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
        <time_frame>Up to Day 15</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [Mass x Time/Volume] (AUClast), Part 2</title>
          <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O5" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O6" value="NA">Statistical analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Terminal Elimination Half-life [Time] (T1/2), Part 2</title>
        <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
        <time_frame>Up to Day 15</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Terminal Elimination Half-life [Time] (T1/2), Part 2</title>
          <description>Plasma concentrations were quantitated using a high performance liquid chromatography/tandem mass spectometry method. Timepoints of assessment for Arms 1-4 were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose; and Day 15: 0h. Timepoints of assessment for LHA Highest BID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h post-dose; and Day 15: 0h. Timepoints of assessment for LHA510 Highest TID were Days 1 and 7: 0h (pre-dose), 0.25h, 0.5h, 1h, 2h, 4h, 0h (pre-2nd dose), 0.5h, 2h, 0h (pre-3rd dose), 0.25h, 0.5h, 1h, 2h, 4h, 12h post-dose; and Day 15: 0h.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O2" value="NA">The analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O3" value="NA">The analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O4" value="NA">The analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O5" value="NA">The analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                    <measurement group_id="O6" value="NA">The analysis was not conducted because the concentration was too low to allow reliable estimation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 1</title>
        <description>Diastolic blood pressure (pressure in the arteries when the heart rests between beats) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
        <time_frame>Day 1: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 1</title>
          <description>Diastolic blood pressure (pressure in the arteries when the heart rests between beats) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
          <population>This analysis population includes all enrolled subjects in Part 1.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.19"/>
                    <measurement group_id="O2" value="-5.5" spread="3.35"/>
                    <measurement group_id="O3" value="2.8" spread="3.14"/>
                    <measurement group_id="O4" value="4.1" spread="3.12"/>
                    <measurement group_id="O5" value="-5.2" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.50 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.19"/>
                    <measurement group_id="O2" value="-0.2" spread="3.35"/>
                    <measurement group_id="O3" value="5.6" spread="3.14"/>
                    <measurement group_id="O4" value="7.6" spread="3.12"/>
                    <measurement group_id="O5" value="2.1" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.19"/>
                    <measurement group_id="O2" value="2.2" spread="3.35"/>
                    <measurement group_id="O3" value="5.3" spread="3.14"/>
                    <measurement group_id="O4" value="5.1" spread="3.12"/>
                    <measurement group_id="O5" value="-1.4" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.19"/>
                    <measurement group_id="O2" value="-1.0" spread="3.35"/>
                    <measurement group_id="O3" value="-1.6" spread="3.14"/>
                    <measurement group_id="O4" value="-0.9" spread="3.12"/>
                    <measurement group_id="O5" value="-6.5" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="3.19"/>
                    <measurement group_id="O2" value="3.7" spread="3.35"/>
                    <measurement group_id="O3" value="4.3" spread="3.14"/>
                    <measurement group_id="O4" value="4.1" spread="3.12"/>
                    <measurement group_id="O5" value="2.4" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.19"/>
                    <measurement group_id="O2" value="1.2" spread="3.35"/>
                    <measurement group_id="O3" value="2.9" spread="3.14"/>
                    <measurement group_id="O4" value="3.1" spread="3.12"/>
                    <measurement group_id="O5" value="-6.1" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.19"/>
                    <measurement group_id="O2" value="1.5" spread="3.35"/>
                    <measurement group_id="O3" value="4.6" spread="3.14"/>
                    <measurement group_id="O4" value="2.5" spread="3.12"/>
                    <measurement group_id="O5" value="0.0" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="3.19"/>
                    <measurement group_id="O2" value="1.7" spread="3.35"/>
                    <measurement group_id="O3" value="4.1" spread="3.14"/>
                    <measurement group_id="O4" value="-2.2" spread="3.12"/>
                    <measurement group_id="O5" value="-3.9" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="3.19"/>
                    <measurement group_id="O2" value="5.5" spread="3.35"/>
                    <measurement group_id="O3" value="6.1" spread="3.14"/>
                    <measurement group_id="O4" value="5.3" spread="3.12"/>
                    <measurement group_id="O5" value="4.0" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing a Non-serious Adverse Event, Part I</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.</description>
        <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing a Non-serious Adverse Event, Part I</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.</description>
          <population>This analysis population includes all enrolled subjects in Part 1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing a Non-serious Adverse Event, Part 2</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.</description>
        <time_frame>From time of consent until 30 days after stopping the trial/study drug</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
          <group group_id="O7">
            <title>Vehicle, Part 2</title>
            <description>1 drop instilled in the study eye once, twice, or three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing a Non-serious Adverse Event, Part 2</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 1</title>
        <description>Systolic blood pressure (pressure when the heart is contracting) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
        <time_frame>Day 1: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 1</title>
          <description>Systolic blood pressure (pressure when the heart is contracting) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
          <population>This analysis population includes all enrolled subjects in Part 1.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="5.00"/>
                    <measurement group_id="O2" value="0.5" spread="5.11"/>
                    <measurement group_id="O3" value="0.5" spread="5.05"/>
                    <measurement group_id="O4" value="5.3" spread="4.97"/>
                    <measurement group_id="O5" value="0.2" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.50 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="5.00"/>
                    <measurement group_id="O2" value="0.1" spread="5.11"/>
                    <measurement group_id="O3" value="-0.3" spread="5.05"/>
                    <measurement group_id="O4" value="6.9" spread="4.97"/>
                    <measurement group_id="O5" value="4.9" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="5.00"/>
                    <measurement group_id="O2" value="2.8" spread="5.11"/>
                    <measurement group_id="O3" value="1.2" spread="5.05"/>
                    <measurement group_id="O4" value="2.9" spread="4.97"/>
                    <measurement group_id="O5" value="4.4" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="5.00"/>
                    <measurement group_id="O2" value="5.3" spread="5.11"/>
                    <measurement group_id="O3" value="0.5" spread="5.05"/>
                    <measurement group_id="O4" value="9.8" spread="4.97"/>
                    <measurement group_id="O5" value="1.3" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="5.00"/>
                    <measurement group_id="O2" value="9.3" spread="5.11"/>
                    <measurement group_id="O3" value="4.7" spread="5.05"/>
                    <measurement group_id="O4" value="5.4" spread="4.97"/>
                    <measurement group_id="O5" value="-0.9" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="5.00"/>
                    <measurement group_id="O2" value="10.5" spread="5.11"/>
                    <measurement group_id="O3" value="0.7" spread="5.05"/>
                    <measurement group_id="O4" value="4.9" spread="4.97"/>
                    <measurement group_id="O5" value="-4.6" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="5.00"/>
                    <measurement group_id="O2" value="4.3" spread="5.11"/>
                    <measurement group_id="O3" value="2.2" spread="5.05"/>
                    <measurement group_id="O4" value="14.1" spread="4.97"/>
                    <measurement group_id="O5" value="-2.6" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="5.00"/>
                    <measurement group_id="O2" value="11.8" spread="5.11"/>
                    <measurement group_id="O3" value="-3.0" spread="5.05"/>
                    <measurement group_id="O4" value="5.3" spread="4.97"/>
                    <measurement group_id="O5" value="-1.9" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="5.00"/>
                    <measurement group_id="O2" value="9.6" spread="5.11"/>
                    <measurement group_id="O3" value="2.3" spread="5.05"/>
                    <measurement group_id="O4" value="8.9" spread="4.97"/>
                    <measurement group_id="O5" value="2.1" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 1</title>
        <description>Mean arterial blood pressure (average pressure in the arteries during one cardiac cycle) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
        <time_frame>Day 1: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, Part 1</title>
            <description>1 drop instilled in the study eye as a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 1</title>
          <description>Mean arterial blood pressure (average pressure in the arteries during one cardiac cycle) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
          <population>This analysis population includes all enrolled subjects in Part 1.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.25"/>
                    <measurement group_id="O2" value="-4.4" spread="3.52"/>
                    <measurement group_id="O3" value="2.4" spread="3.31"/>
                    <measurement group_id="O4" value="4.7" spread="3.26"/>
                    <measurement group_id="O5" value="-3.4" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.50 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.25"/>
                    <measurement group_id="O2" value="-0.9" spread="3.52"/>
                    <measurement group_id="O3" value="4.0" spread="3.31"/>
                    <measurement group_id="O4" value="7.6" spread="3.26"/>
                    <measurement group_id="O5" value="3.1" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.25"/>
                    <measurement group_id="O2" value="1.5" spread="3.52"/>
                    <measurement group_id="O3" value="4.3" spread="3.31"/>
                    <measurement group_id="O4" value="4.6" spread="3.26"/>
                    <measurement group_id="O5" value="0.6" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="3.25"/>
                    <measurement group_id="O2" value="0.3" spread="3.52"/>
                    <measurement group_id="O3" value="-0.5" spread="3.31"/>
                    <measurement group_id="O4" value="2.9" spread="3.26"/>
                    <measurement group_id="O5" value="-3.9" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.25"/>
                    <measurement group_id="O2" value="4.7" spread="3.52"/>
                    <measurement group_id="O3" value="4.8" spread="3.31"/>
                    <measurement group_id="O4" value="4.8" spread="3.26"/>
                    <measurement group_id="O5" value="1.3" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="3.25"/>
                    <measurement group_id="O2" value="3.4" spread="3.52"/>
                    <measurement group_id="O3" value="2.6" spread="3.31"/>
                    <measurement group_id="O4" value="4.0" spread="3.26"/>
                    <measurement group_id="O5" value="-5.6" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.25"/>
                    <measurement group_id="O2" value="1.6" spread="3.52"/>
                    <measurement group_id="O3" value="4.2" spread="3.31"/>
                    <measurement group_id="O4" value="6.6" spread="3.26"/>
                    <measurement group_id="O5" value="-0.8" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.25"/>
                    <measurement group_id="O2" value="4.2" spread="3.52"/>
                    <measurement group_id="O3" value="2.2" spread="3.31"/>
                    <measurement group_id="O4" value="0.5" spread="3.26"/>
                    <measurement group_id="O5" value="-3.2" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24.00 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="3.25"/>
                    <measurement group_id="O2" value="6.0" spread="3.52"/>
                    <measurement group_id="O3" value="5.3" spread="3.31"/>
                    <measurement group_id="O4" value="6.7" spread="3.26"/>
                    <measurement group_id="O5" value="3.4" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 2</title>
        <description>Diastolic blood pressure (pressure in the arteries when the heart rests between beats) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
        <time_frame>Day 1 and 7: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
          <group group_id="O7">
            <title>Vehicle, Part 2</title>
            <description>1 drop instilled in the study eye once, twice, or three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Each Post Dose Timepoint, Part 2</title>
          <description>Diastolic blood pressure (pressure in the arteries when the heart rests between beats) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.25 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.94"/>
                    <measurement group_id="O2" value="-4.4" spread="2.96"/>
                    <measurement group_id="O3" value="-0.6" spread="2.95"/>
                    <measurement group_id="O4" value="-2.9" spread="2.93"/>
                    <measurement group_id="O5" value="2.5" spread="2.93"/>
                    <measurement group_id="O6" value="0.6" spread="2.93"/>
                    <measurement group_id="O7" value="-0.5" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.50 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.94"/>
                    <measurement group_id="O2" value="-7.2" spread="2.96"/>
                    <measurement group_id="O3" value="-4.5" spread="2.95"/>
                    <measurement group_id="O4" value="-4.6" spread="2.93"/>
                    <measurement group_id="O5" value="4.3" spread="2.93"/>
                    <measurement group_id="O6" value="-2.2" spread="2.93"/>
                    <measurement group_id="O7" value="2.4" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.94"/>
                    <measurement group_id="O2" value="-7.7" spread="2.96"/>
                    <measurement group_id="O3" value="0.2" spread="2.95"/>
                    <measurement group_id="O4" value="1.9" spread="2.93"/>
                    <measurement group_id="O5" value="1.7" spread="2.93"/>
                    <measurement group_id="O6" value="-5.4" spread="2.93"/>
                    <measurement group_id="O7" value="0.3" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="2.94"/>
                    <measurement group_id="O2" value="-6.5" spread="2.96"/>
                    <measurement group_id="O3" value="1.2" spread="2.95"/>
                    <measurement group_id="O4" value="-4.1" spread="2.93"/>
                    <measurement group_id="O5" value="-4.2" spread="2.93"/>
                    <measurement group_id="O6" value="-6.7" spread="2.93"/>
                    <measurement group_id="O7" value="-4.9" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.94"/>
                    <measurement group_id="O2" value="-4.0" spread="2.96"/>
                    <measurement group_id="O3" value="-5.5" spread="2.95"/>
                    <measurement group_id="O4" value="0.9" spread="2.93"/>
                    <measurement group_id="O5" value="-1.2" spread="2.93"/>
                    <measurement group_id="O6" value="-2.4" spread="2.93"/>
                    <measurement group_id="O7" value="-0.2" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="2.94"/>
                    <measurement group_id="O2" value="-6.9" spread="2.96"/>
                    <measurement group_id="O3" value="-3.3" spread="2.95"/>
                    <measurement group_id="O4" value="-4.1" spread="2.93"/>
                    <measurement group_id="O5" value="-2.2" spread="2.93"/>
                    <measurement group_id="O6" value="-5.9" spread="2.93"/>
                    <measurement group_id="O7" value="-5.3" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.94"/>
                    <measurement group_id="O2" value="2.1" spread="2.96"/>
                    <measurement group_id="O3" value="-2.0" spread="2.95"/>
                    <measurement group_id="O4" value="1.4" spread="2.93"/>
                    <measurement group_id="O5" value="4.3" spread="2.93"/>
                    <measurement group_id="O6" value="1.3" spread="2.93"/>
                    <measurement group_id="O7" value="5.7" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.94"/>
                    <measurement group_id="O2" value="1.0" spread="2.96"/>
                    <measurement group_id="O3" value="-1.3" spread="2.95"/>
                    <measurement group_id="O4" value="-2.1" spread="2.93"/>
                    <measurement group_id="O5" value="7.2" spread="2.93"/>
                    <measurement group_id="O6" value="-0.4" spread="2.93"/>
                    <measurement group_id="O7" value="0.4" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.94"/>
                    <measurement group_id="O2" value="-2.5" spread="2.96"/>
                    <measurement group_id="O3" value="3.9" spread="2.95"/>
                    <measurement group_id="O4" value="2.3" spread="2.93"/>
                    <measurement group_id="O5" value="-2.7" spread="2.93"/>
                    <measurement group_id="O6" value="-0.7" spread="2.93"/>
                    <measurement group_id="O7" value="2.7" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.25 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="2.94"/>
                    <measurement group_id="O2" value="-6.2" spread="2.96"/>
                    <measurement group_id="O3" value="-3.3" spread="2.95"/>
                    <measurement group_id="O4" value="-1.7" spread="2.93"/>
                    <measurement group_id="O5" value="-2.8" spread="2.93"/>
                    <measurement group_id="O6" value="-2.4" spread="2.93"/>
                    <measurement group_id="O7" value="-3.6" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.50 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="2.94"/>
                    <measurement group_id="O2" value="-5.7" spread="2.96"/>
                    <measurement group_id="O3" value="-10.0" spread="2.95"/>
                    <measurement group_id="O4" value="-2.1" spread="2.93"/>
                    <measurement group_id="O5" value="-3.2" spread="2.93"/>
                    <measurement group_id="O6" value="1.6" spread="2.93"/>
                    <measurement group_id="O7" value="-2.8" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="2.94"/>
                    <measurement group_id="O2" value="-4.9" spread="2.96"/>
                    <measurement group_id="O3" value="-4.3" spread="2.95"/>
                    <measurement group_id="O4" value="-3.1" spread="2.93"/>
                    <measurement group_id="O5" value="-6.5" spread="2.93"/>
                    <measurement group_id="O6" value="-2.2" spread="2.93"/>
                    <measurement group_id="O7" value="-2.9" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.94"/>
                    <measurement group_id="O2" value="-6.4" spread="2.96"/>
                    <measurement group_id="O3" value="-8.3" spread="2.95"/>
                    <measurement group_id="O4" value="-4.7" spread="2.93"/>
                    <measurement group_id="O5" value="-0.7" spread="2.93"/>
                    <measurement group_id="O6" value="-5.4" spread="2.93"/>
                    <measurement group_id="O7" value="-9.6" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="2.94"/>
                    <measurement group_id="O2" value="-6.7" spread="2.96"/>
                    <measurement group_id="O3" value="-9.3" spread="2.95"/>
                    <measurement group_id="O4" value="-3.6" spread="2.93"/>
                    <measurement group_id="O5" value="-8.2" spread="2.93"/>
                    <measurement group_id="O6" value="-2.4" spread="2.93"/>
                    <measurement group_id="O7" value="-7.8" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="2.94"/>
                    <measurement group_id="O2" value="0.3" spread="2.96"/>
                    <measurement group_id="O3" value="-10.3" spread="2.95"/>
                    <measurement group_id="O4" value="-5.6" spread="2.93"/>
                    <measurement group_id="O5" value="-8.8" spread="2.93"/>
                    <measurement group_id="O6" value="-6.4" spread="2.93"/>
                    <measurement group_id="O7" value="-5.3" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.94"/>
                    <measurement group_id="O2" value="1.0" spread="2.96"/>
                    <measurement group_id="O3" value="-6.1" spread="2.95"/>
                    <measurement group_id="O4" value="-2.7" spread="2.93"/>
                    <measurement group_id="O5" value="-3.0" spread="2.93"/>
                    <measurement group_id="O6" value="1.3" spread="2.93"/>
                    <measurement group_id="O7" value="-2.4" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="2.94"/>
                    <measurement group_id="O2" value="-1.0" spread="2.96"/>
                    <measurement group_id="O3" value="-7.1" spread="2.95"/>
                    <measurement group_id="O4" value="-3.7" spread="2.93"/>
                    <measurement group_id="O5" value="-2.3" spread="2.93"/>
                    <measurement group_id="O6" value="-2.7" spread="2.93"/>
                    <measurement group_id="O7" value="-3.0" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.94"/>
                    <measurement group_id="O2" value="-2.2" spread="2.96"/>
                    <measurement group_id="O3" value="-7.5" spread="2.95"/>
                    <measurement group_id="O4" value="-3.7" spread="2.93"/>
                    <measurement group_id="O5" value="-1.2" spread="2.93"/>
                    <measurement group_id="O6" value="-1.4" spread="2.93"/>
                    <measurement group_id="O7" value="0.4" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 2</title>
        <description>Systolic blood pressure (pressure when the heart is contracting) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
        <time_frame>Day 1 and 7: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
          <group group_id="O7">
            <title>Vehicle, Part 2</title>
            <description>1 drop instilled in the study eye once, twice, or three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Each Post Dose Timepoint, Part 2</title>
          <description>Systolic blood pressure (pressure when the heart is contracting) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.25 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="5.70"/>
                    <measurement group_id="O2" value="-11.1" spread="5.90"/>
                    <measurement group_id="O3" value="-4.1" spread="5.70"/>
                    <measurement group_id="O4" value="-4.8" spread="5.74"/>
                    <measurement group_id="O5" value="0.6" spread="5.72"/>
                    <measurement group_id="O6" value="-4.1" spread="5.69"/>
                    <measurement group_id="O7" value="1.0" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.50 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="5.70"/>
                    <measurement group_id="O2" value="-12.7" spread="5.90"/>
                    <measurement group_id="O3" value="-0.4" spread="5.70"/>
                    <measurement group_id="O4" value="-11.4" spread="5.74"/>
                    <measurement group_id="O5" value="-5.4" spread="5.72"/>
                    <measurement group_id="O6" value="-5.8" spread="5.69"/>
                    <measurement group_id="O7" value="0.8" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="5.70"/>
                    <measurement group_id="O2" value="-13.1" spread="5.90"/>
                    <measurement group_id="O3" value="3.4" spread="5.70"/>
                    <measurement group_id="O4" value="-8.9" spread="5.74"/>
                    <measurement group_id="O5" value="-3.1" spread="5.72"/>
                    <measurement group_id="O6" value="-8.9" spread="5.69"/>
                    <measurement group_id="O7" value="0.8" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="5.70"/>
                    <measurement group_id="O2" value="-3.9" spread="5.90"/>
                    <measurement group_id="O3" value="-0.9" spread="5.70"/>
                    <measurement group_id="O4" value="-6.4" spread="5.74"/>
                    <measurement group_id="O5" value="-5.6" spread="5.72"/>
                    <measurement group_id="O6" value="-10.6" spread="5.69"/>
                    <measurement group_id="O7" value="-4.6" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="5.70"/>
                    <measurement group_id="O2" value="-5.4" spread="5.90"/>
                    <measurement group_id="O3" value="-9.9" spread="5.70"/>
                    <measurement group_id="O4" value="0.7" spread="5.74"/>
                    <measurement group_id="O5" value="-3.4" spread="5.72"/>
                    <measurement group_id="O6" value="-0.4" spread="5.69"/>
                    <measurement group_id="O7" value="-0.4" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="5.70"/>
                    <measurement group_id="O2" value="-15.6" spread="5.90"/>
                    <measurement group_id="O3" value="-8.6" spread="5.70"/>
                    <measurement group_id="O4" value="0.4" spread="5.74"/>
                    <measurement group_id="O5" value="-2.2" spread="5.72"/>
                    <measurement group_id="O6" value="-6.9" spread="5.69"/>
                    <measurement group_id="O7" value="-10.1" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="5.70"/>
                    <measurement group_id="O2" value="11.1" spread="5.90"/>
                    <measurement group_id="O3" value="-9.8" spread="5.70"/>
                    <measurement group_id="O4" value="-1.4" spread="5.74"/>
                    <measurement group_id="O5" value="-6.1" spread="5.72"/>
                    <measurement group_id="O6" value="6.1" spread="5.69"/>
                    <measurement group_id="O7" value="5.1" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="5.70"/>
                    <measurement group_id="O2" value="11.8" spread="5.90"/>
                    <measurement group_id="O3" value="-8.8" spread="5.70"/>
                    <measurement group_id="O4" value="-3.9" spread="5.74"/>
                    <measurement group_id="O5" value="3.4" spread="5.72"/>
                    <measurement group_id="O6" value="1.2" spread="5.69"/>
                    <measurement group_id="O7" value="5.9" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="5.70"/>
                    <measurement group_id="O2" value="0.1" spread="5.90"/>
                    <measurement group_id="O3" value="-2.6" spread="5.70"/>
                    <measurement group_id="O4" value="7.7" spread="5.74"/>
                    <measurement group_id="O5" value="-6.9" spread="5.72"/>
                    <measurement group_id="O6" value="-6.8" spread="5.69"/>
                    <measurement group_id="O7" value="2.6" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.25 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.70"/>
                    <measurement group_id="O2" value="-7.6" spread="5.90"/>
                    <measurement group_id="O3" value="-9.4" spread="5.70"/>
                    <measurement group_id="O4" value="-2.3" spread="5.74"/>
                    <measurement group_id="O5" value="-13.7" spread="5.72"/>
                    <measurement group_id="O6" value="-11.3" spread="5.69"/>
                    <measurement group_id="O7" value="-3.3" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.50 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="5.70"/>
                    <measurement group_id="O2" value="-6.2" spread="5.90"/>
                    <measurement group_id="O3" value="-14.9" spread="5.70"/>
                    <measurement group_id="O4" value="-8.8" spread="5.74"/>
                    <measurement group_id="O5" value="-9.9" spread="5.72"/>
                    <measurement group_id="O6" value="-9.9" spread="5.69"/>
                    <measurement group_id="O7" value="-6.4" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="5.70"/>
                    <measurement group_id="O2" value="-9.4" spread="5.90"/>
                    <measurement group_id="O3" value="-9.4" spread="5.70"/>
                    <measurement group_id="O4" value="-4.6" spread="5.74"/>
                    <measurement group_id="O5" value="-18.6" spread="5.72"/>
                    <measurement group_id="O6" value="-6.1" spread="5.69"/>
                    <measurement group_id="O7" value="-3.9" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.70"/>
                    <measurement group_id="O2" value="-6.9" spread="5.90"/>
                    <measurement group_id="O3" value="-9.8" spread="5.70"/>
                    <measurement group_id="O4" value="-6.1" spread="5.74"/>
                    <measurement group_id="O5" value="-14.7" spread="5.72"/>
                    <measurement group_id="O6" value="-0.4" spread="5.69"/>
                    <measurement group_id="O7" value="-12.3" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="5.70"/>
                    <measurement group_id="O2" value="-5.1" spread="5.90"/>
                    <measurement group_id="O3" value="-12.4" spread="5.70"/>
                    <measurement group_id="O4" value="-3.8" spread="5.74"/>
                    <measurement group_id="O5" value="-9.4" spread="5.72"/>
                    <measurement group_id="O6" value="-8.9" spread="5.69"/>
                    <measurement group_id="O7" value="-17.4" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="5.70"/>
                    <measurement group_id="O2" value="4.3" spread="5.90"/>
                    <measurement group_id="O3" value="-18.8" spread="5.70"/>
                    <measurement group_id="O4" value="-6.6" spread="5.74"/>
                    <measurement group_id="O5" value="-7.7" spread="5.72"/>
                    <measurement group_id="O6" value="-5.4" spread="5.69"/>
                    <measurement group_id="O7" value="-3.3" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.70"/>
                    <measurement group_id="O2" value="15.6" spread="5.90"/>
                    <measurement group_id="O3" value="-9.8" spread="5.70"/>
                    <measurement group_id="O4" value="0.6" spread="5.74"/>
                    <measurement group_id="O5" value="-10.9" spread="5.72"/>
                    <measurement group_id="O6" value="0.1" spread="5.69"/>
                    <measurement group_id="O7" value="-0.9" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="5.70"/>
                    <measurement group_id="O2" value="8.4" spread="5.90"/>
                    <measurement group_id="O3" value="-10.9" spread="5.70"/>
                    <measurement group_id="O4" value="-9.6" spread="5.74"/>
                    <measurement group_id="O5" value="-7.6" spread="5.72"/>
                    <measurement group_id="O6" value="-4.9" spread="5.69"/>
                    <measurement group_id="O7" value="-5.5" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="5.70"/>
                    <measurement group_id="O2" value="0.6" spread="5.90"/>
                    <measurement group_id="O3" value="-23.1" spread="5.70"/>
                    <measurement group_id="O4" value="-4.4" spread="5.74"/>
                    <measurement group_id="O5" value="-4.4" spread="5.72"/>
                    <measurement group_id="O6" value="0.6" spread="5.69"/>
                    <measurement group_id="O7" value="7.3" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 2</title>
        <description>Mean arterial blood pressure (average pressure in the arteries during one cardiac cycle) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
        <time_frame>Day 1 and 7: 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h and 24h post-dose</time_frame>
        <population>This analysis population includes all enrolled subjects in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>LHA510 Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>LHA510 Next Lowest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>LHA510 Next Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>LHA510 Highest, Part 2</title>
            <description>1 drop instilled in the study eye once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>LHA510 Highest BID, Part 2</title>
            <description>1 drop instilled in the study eye twice daily for 7 days</description>
          </group>
          <group group_id="O6">
            <title>LHA510 Highest TID, Part 2</title>
            <description>1 drop instilled in the study eye three times daily for 7 days</description>
          </group>
          <group group_id="O7">
            <title>Vehicle, Part 2</title>
            <description>One drop instilled in the study eye once, twice, or three times daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Mean Arterial Blood Pressure at Each Post Dose Timepoint, Part 2</title>
          <description>Mean arterial blood pressure (average pressure in the arteries during one cardiac cycle) was measured using an automated validated device, with an appropriately sized cuff, and assessed in the sitting position after the subject had rested for at least 3 minutes, and again (when required) after 3 minutes in the standing position.</description>
          <population>This analysis population includes all enrolled subjects in Part 2.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 0.25 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.34"/>
                    <measurement group_id="O2" value="-6.8" spread="3.41"/>
                    <measurement group_id="O3" value="-1.7" spread="3.35"/>
                    <measurement group_id="O4" value="-3.5" spread="3.33"/>
                    <measurement group_id="O5" value="1.9" spread="3.33"/>
                    <measurement group_id="O6" value="-1.0" spread="3.33"/>
                    <measurement group_id="O7" value="-0.0" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 0.50 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="3.34"/>
                    <measurement group_id="O2" value="-9.2" spread="3.41"/>
                    <measurement group_id="O3" value="-3.1" spread="3.35"/>
                    <measurement group_id="O4" value="-6.8" spread="3.33"/>
                    <measurement group_id="O5" value="1.1" spread="3.33"/>
                    <measurement group_id="O6" value="-3.4" spread="3.33"/>
                    <measurement group_id="O7" value="1.8" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="3.34"/>
                    <measurement group_id="O2" value="-9.7" spread="3.41"/>
                    <measurement group_id="O3" value="1.3" spread="3.35"/>
                    <measurement group_id="O4" value="-1.6" spread="3.33"/>
                    <measurement group_id="O5" value="0.1" spread="3.33"/>
                    <measurement group_id="O6" value="-6.6" spread="3.33"/>
                    <measurement group_id="O7" value="0.4" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="3.34"/>
                    <measurement group_id="O2" value="-5.8" spread="3.41"/>
                    <measurement group_id="O3" value="0.6" spread="3.35"/>
                    <measurement group_id="O4" value="-4.8" spread="3.33"/>
                    <measurement group_id="O5" value="-4.6" spread="3.33"/>
                    <measurement group_id="O6" value="-8.1" spread="3.33"/>
                    <measurement group_id="O7" value="-4.8" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.34"/>
                    <measurement group_id="O2" value="-4.7" spread="3.41"/>
                    <measurement group_id="O3" value="-6.9" spread="3.35"/>
                    <measurement group_id="O4" value="0.9" spread="3.33"/>
                    <measurement group_id="O5" value="-1.9" spread="3.33"/>
                    <measurement group_id="O6" value="-1.8" spread="3.33"/>
                    <measurement group_id="O7" value="-0.3" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="3.34"/>
                    <measurement group_id="O2" value="-10.0" spread="3.41"/>
                    <measurement group_id="O3" value="-5.0" spread="3.35"/>
                    <measurement group_id="O4" value="-2.5" spread="3.33"/>
                    <measurement group_id="O5" value="-2.1" spread="3.33"/>
                    <measurement group_id="O6" value="-6.3" spread="3.33"/>
                    <measurement group_id="O7" value="-6.9" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.34"/>
                    <measurement group_id="O2" value="4.9" spread="3.41"/>
                    <measurement group_id="O3" value="-4.5" spread="3.35"/>
                    <measurement group_id="O4" value="0.5" spread="3.33"/>
                    <measurement group_id="O5" value="0.9" spread="3.33"/>
                    <measurement group_id="O6" value="2.8" spread="3.33"/>
                    <measurement group_id="O7" value="5.5" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.34"/>
                    <measurement group_id="O2" value="4.4" spread="3.41"/>
                    <measurement group_id="O3" value="-3.7" spread="3.35"/>
                    <measurement group_id="O4" value="-2.6" spread="3.33"/>
                    <measurement group_id="O5" value="6.0" spread="3.33"/>
                    <measurement group_id="O6" value="0.1" spread="3.33"/>
                    <measurement group_id="O7" value="2.2" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 24.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.34"/>
                    <measurement group_id="O2" value="-1.8" spread="3.41"/>
                    <measurement group_id="O3" value="1.8" spread="3.35"/>
                    <measurement group_id="O4" value="4.1" spread="3.33"/>
                    <measurement group_id="O5" value="-4.0" spread="3.33"/>
                    <measurement group_id="O6" value="-2.8" spread="3.33"/>
                    <measurement group_id="O7" value="2.6" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.25 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="3.34"/>
                    <measurement group_id="O2" value="-6.8" spread="3.41"/>
                    <measurement group_id="O3" value="-5.3" spread="3.35"/>
                    <measurement group_id="O4" value="-1.9" spread="3.33"/>
                    <measurement group_id="O5" value="-6.4" spread="3.33"/>
                    <measurement group_id="O6" value="-5.4" spread="3.33"/>
                    <measurement group_id="O7" value="-3.5" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 0.50 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="3.34"/>
                    <measurement group_id="O2" value="-6.1" spread="3.41"/>
                    <measurement group_id="O3" value="-11.6" spread="3.35"/>
                    <measurement group_id="O4" value="-4.3" spread="3.33"/>
                    <measurement group_id="O5" value="-5.4" spread="3.33"/>
                    <measurement group_id="O6" value="-2.3" spread="3.33"/>
                    <measurement group_id="O7" value="-4.0" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 1.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="3.34"/>
                    <measurement group_id="O2" value="-6.6" spread="3.41"/>
                    <measurement group_id="O3" value="-5.9" spread="3.35"/>
                    <measurement group_id="O4" value="-3.5" spread="3.33"/>
                    <measurement group_id="O5" value="-10.5" spread="3.33"/>
                    <measurement group_id="O6" value="-3.6" spread="3.33"/>
                    <measurement group_id="O7" value="-3.3" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 2.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="3.34"/>
                    <measurement group_id="O2" value="-6.7" spread="3.41"/>
                    <measurement group_id="O3" value="-8.7" spread="3.35"/>
                    <measurement group_id="O4" value="-5.1" spread="3.33"/>
                    <measurement group_id="O5" value="-5.3" spread="3.33"/>
                    <measurement group_id="O6" value="-3.8" spread="3.33"/>
                    <measurement group_id="O7" value="-10.5" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 4.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="3.34"/>
                    <measurement group_id="O2" value="-6.3" spread="3.41"/>
                    <measurement group_id="O3" value="-10.3" spread="3.35"/>
                    <measurement group_id="O4" value="-3.6" spread="3.33"/>
                    <measurement group_id="O5" value="-8.5" spread="3.33"/>
                    <measurement group_id="O6" value="-4.6" spread="3.33"/>
                    <measurement group_id="O7" value="-11.0" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 6.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="3.34"/>
                    <measurement group_id="O2" value="1.4" spread="3.41"/>
                    <measurement group_id="O3" value="-13.1" spread="3.35"/>
                    <measurement group_id="O4" value="-5.9" spread="3.33"/>
                    <measurement group_id="O5" value="-8.4" spread="3.33"/>
                    <measurement group_id="O6" value="-6.1" spread="3.33"/>
                    <measurement group_id="O7" value="-4.6" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 8.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="3.34"/>
                    <measurement group_id="O2" value="5.7" spread="3.41"/>
                    <measurement group_id="O3" value="-7.3" spread="3.35"/>
                    <measurement group_id="O4" value="-1.6" spread="3.33"/>
                    <measurement group_id="O5" value="-5.6" spread="3.33"/>
                    <measurement group_id="O6" value="0.8" spread="3.33"/>
                    <measurement group_id="O7" value="-1.9" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 12.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="3.34"/>
                    <measurement group_id="O2" value="1.9" spread="3.41"/>
                    <measurement group_id="O3" value="-8.3" spread="3.35"/>
                    <measurement group_id="O4" value="-5.6" spread="3.33"/>
                    <measurement group_id="O5" value="-4.0" spread="3.33"/>
                    <measurement group_id="O6" value="-3.5" spread="3.33"/>
                    <measurement group_id="O7" value="-3.8" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, 24.00 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.34"/>
                    <measurement group_id="O2" value="-1.5" spread="3.41"/>
                    <measurement group_id="O3" value="-12.6" spread="3.35"/>
                    <measurement group_id="O4" value="-3.9" spread="3.33"/>
                    <measurement group_id="O5" value="-2.2" spread="3.33"/>
                    <measurement group_id="O6" value="-0.8" spread="3.33"/>
                    <measurement group_id="O7" value="2.7" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected for the duration of the study (Feb 2014 – Jun 2014). This analysis group includes all enrolled subjects.</time_frame>
      <desc>An AE is defined as any untoward medical occurrence in a patient who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. AEs were obtained as solicited comments from the study subjects and observations by the study Investigator, as outlined in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>LHA510 Lowest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="E2">
          <title>LHA510 Next Lowest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="E3">
          <title>LHA510 Next Highest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="E4">
          <title>LHA510 Highest, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="E5">
          <title>Vehicle, Part 1</title>
          <description>1 drop instilled in the study eye as a single dose</description>
        </group>
        <group group_id="E6">
          <title>LHA510 Lowest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="E7">
          <title>LHA510 Next Lowest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="E8">
          <title>LHA510 Next Highest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="E9">
          <title>LHA510 Highest, Part 2</title>
          <description>1 drop instilled in the study eye once daily for 7 days</description>
        </group>
        <group group_id="E10">
          <title>LHA510 Highest BID, Part 2</title>
          <description>1 drop instilled in the study eye twice daily for 7 days</description>
        </group>
        <group group_id="E11">
          <title>LHA510 Highest TID, Part 2</title>
          <description>1 drop instilled in the study eye three times daily for 7 days</description>
        </group>
        <group group_id="E12">
          <title>Vehicle, Part 2</title>
          <description>1 drop instilled in the study eye once, twice, or three times daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Clinical Scientist, CA CSI ID</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

